LifeBond

Biosurgery Products for Preventing Postoperative Complications

Health Tech & Life Sciences
Acquired (Inactive) by Bard Medical on Jan 2020 - closed due to acquisition
Follow

Company Overview

Snapshot

Founded in January 2007 by Orahn Preiss-bloom and Ishay Attar, LifeBond operated with 11–50 employees. The company raised a total of $56.5 million across 5 funding rounds from 5 investors. LifeBond was acquired by Bard Medical in January 2020.

Business overview

LifeBond develops and manufactures medical devices for biosurgery and tissue repair, focusing on preventing postoperative complications. The company's product pipeline utilizes 100% natural biosurgical materials. Key products include LifeSeal Surgical Sealant, designed to minimize staple-line leakage in bariatric and colorectal procedures, and LifeMesh Self-Fixating Mesh, which provides atraumatic tissue fixation for hernia repair. LifeBond operates within the Health Tech & Life Sciences sector, specifically targeting medical devices and biomaterials for surgeons and hospitals.

Strategic signal

In January 2020, LifeBond was acquired by Bard Medical. This acquisition signals a successful exit for LifeBond, validating its biosurgery and tissue repair technologies and demonstrating the strategic value of its product pipeline to larger medical device corporations.

Log in to access full profile

Company Intelligence Q&A

What was LifeBond's exit event?
LifeBond was acquired by Bard Medical in January 2020. The terms of the acquisition were not disclosed.
When did LifeBond receive CE approval for its surgical product?
In April 2016, LifeBond obtained CE approval for its surgical product, LifeSeal Surgical Sealant, which also received FDA fast-track status.
What was the focus of LifeBond's multi-center international pivotal study?
In February 2017, LifeBond's multi-center international pivotal study of the LifeSeal Surgical Sealant for GI resections was actively enrolling patients in the US and Europe.
Which investors participated in LifeBond's May 2011 C Round funding?
In May 2011, LifeBond received funding from investors including Giza Venture Capital.
What is LifeBond's primary product for hernia repair?
LifeBond's LifeMesh Self-Fixating Mesh is designed to provide secure surgical mesh fixation for hernia repair procedures, aiming to reduce postsurgical complications through its embedded adhesive layer.
Log in to access full profile